Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer.
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer.
复制标题
DOI：
10.1586/eem.10.49
复制
发表时间：
2010-09
影响因子：
3.2
通讯作者：
Luo J
中科院分区：
文献类型：
--
作者：
Hu R;Denmeade SR;Luo J
针对雄激素受体信号传导的激素疗法是晚期前列腺癌患者的主要治疗方法。激素治疗诱导的临床缓解的时间长短在治疗的患者中差异很大。为什么有些患者在治疗后进展迅速，而另一些患者则因延长缓解而受益，这是一个尚未解决的问题。雄激素受体信号通路是去势抵抗的关键分子决定因素，也是前列腺癌药物设计的关键靶点。在表征导致去势抵抗性前列腺癌发展的分子过程方面的最新进展，包括多种雄激素受体剪接变体的发现，为合理开发新的临床工具或方法以预测、监测或控制/预防去势环境中的前列腺癌进展提供了机会。
Hormone therapies targeting androgen receptor signaling are the mainstay of treatment for patients with advanced prostate cancer. The length of clinical remission induced by hormone therapies varies substantially among treated patients. Why some patients progress rapidly after treatment while others benefit with prolonged remission is a question that remains unsolved. The androgen receptor signaling pathway is the key molecular determinant of castration resistance, and a key target for prostate cancer drug design. Recent advances in characterizing molecular processes leading to the development of castration-resistant prostate cancer, including the discovery of multiple androgen receptor splicing variants, offer opportunities for rational development of new clinical tools or approaches to predict, monitor or control/prevent prostate cancer progression in the castrate setting.